Ezekiel Emanuel Warns FDA Panel Move Allowing Compounding Pharmacies to Sell Peptides Risks Public Health

Ezekiel Emanuel warns an FDA advisory panel's plan to let compounding pharmacies produce six peptides could jeopardize public health without tighter regulation.

A recent recommendation from an FDA advisory panel to permit compounding pharmacies to produce and sell six peptides has drawn sharp criticism from Penn bioethicist Ezekiel Emanuel. Emanuel argues the move could put people's health at risk by expanding access to biologically active compounds outside the stronger regulatory framework that governs manufactured drugs.

Compounding pharmacies play an important role when patients need individualized doses or formulations not commercially available. However, they traditionally operate under different oversight than pharmaceutical manufacturers. Emanuel and other critics warn that allowing compounding pharmacies to make and distribute peptides — short chains of amino acids that can have powerful biological effects — raises concerns about drug safety, quality control, and consistent dosing.

Key risks include contamination, inaccurate potency, and insufficient sterility testing. Unlike drugs approved through the FDA’s full review process, compounded products may lack comprehensive clinical trial data on safety and effectiveness. For peptides specifically, small manufacturing errors can change how a product behaves in the body, increasing the chance of adverse events. Critics also note gaps in post-market surveillance and limited recall mechanisms for compounded products.

Public health experts emphasize the need for stronger regulation and oversight if compounding pharmacies are to expand their role in producing peptides. That means rigorous quality standards, batch testing, clear labeling, and transparent reporting of adverse reactions. Emanuel’s warning underscores a broader debate over balancing patient access with drug safety: while some patients may benefit from peptide therapies, those benefits should not come at the cost of increased risk from insufficiently regulated production.

Policymakers and the FDA face a choice: adopt strict safeguards and enhanced monitoring if the recommendation moves forward, or maintain tighter controls to ensure peptides remain within the established drug approval system. Consumers and clinicians should be informed about the difference between FDA-approved peptide therapies and compounded alternatives.

Ezekiel Emanuel’s critique is a call to action for regulators, healthcare providers, and the public. Ensuring drug safety, protecting public health, and maintaining trust in the system will require clear rules, robust oversight, and ongoing evaluation of any policy that broadens the role of compounding pharmacies in producing biologically active peptides.

Back